

# AndrÃ© N Vis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8817747/publications.pdf>

Version: 2024-02-01

46  
papers

935  
citations

471061

17  
h-index

500791

28  
g-index

47  
all docs

47  
docs citations

47  
times ranked

1577  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging. <i>BJU International</i> , 2022, 129, 54-62.	1.3	10
2	Selection of patients for nerve sparing surgery in robot-assisted radical prostatectomy. <i>BJUI Compass</i> , 2022, 3, 6-18.	0.7	9
3	Trial-based Cost-effectiveness Analysis of an Immediate Postoperative Mitomycin C Instillation in Patients with Non-muscle-invasive Bladder Cancer. <i>European Urology Open Science</i> , 2022, 37, 7-13.	0.2	1
4	Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation. <i>Clinical Epigenetics</i> , 2022, 14, 19.	1.8	16
5	Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer. <i>Cancers</i> , 2022, 14, 1169.	1.7	15
6	Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study. <i>European Urology</i> , 2022, 82, 97-105.	0.9	37
7	Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer. <i>BJU International</i> , 2022, 129, 768-776.	1.3	7
8	Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.252528.	2.8	11
9	Patient reported outcome measures concerning urinary incontinence after robot assisted radical prostatectomy: development and validation of an online prediction model using clinical parameters, lower urinary tract symptoms and surgical experience. <i>Journal of Robotic Surgery</i> , 2021, 15, 593-602.	1.0	15
10	Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy. <i>European Urology Oncology</i> , 2021, 4, 821-825.	2.6	42
11	A systematic review on mutation markers for bladder cancer diagnosis in urine. <i>BJU International</i> , 2021, 127, 12-27.	1.3	14
12	Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 340-349.	3.3	84
13	Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers. <i>Diagnostics</i> , 2021, 11, 117.	1.3	6
14	SUVs Are Adequate Measures of Lesional <sup>18</sup> F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1264-1269.	2.8	2
15	Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2960-2969.	3.3	8
16	Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 1100-1109.	0.2	4
17	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 1108-1109.	0.2	0
18	Intraoperative Strategies to Reduce Catheter-Related Bladder Discomfort in the Early Postoperative Period after Robot-Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2021, 205, 1671-1680.	0.2	1

#	ARTICLE	IF	CITATIONS
19	Reply by Authors. Journal of Urology, 2021, 205, 1662-1662.	0.2	0
20	Reply by Authors. Journal of Urology, 2021, 205, 1680-1680.	0.2	0
21	The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer. Journal of Urology, 2021, 205, 1655-1662.	0.2	10
22	External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyL: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?. European Urology Open Science, 2021, 28, 47-51.	0.2	2
23	External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study. European Urology, 2021, 80, 234-242.	0.9	35
24	Sexual Dysfunction and Bother Due to Erectile Dysfunction in the Healthy Elderly Male Population: Prevalence from a Systematic Review. European Urology Focus, 2020, 6, 776-790.	1.6	29
25	Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for <sup>18</sup> F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 210-216.	2.8	10
26	Use of gallium-68 prostate-specific membrane antigen positron emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. BJU International, 2020, 125, 206-214.	1.3	80
27	Repeatability of Quantitative <sup>18</sup> F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 1320-1325.	2.8	22
28	Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer. PLoS ONE, 2020, 15, e0239414.	1.1	6
29	A two-gene methylation signature for the diagnosis of bladder cancer in urine. Epigenomics, 2019, 11, 337-347.	1.0	23
30	Objectifying grade in Ta-T1 urothelial carcinomas of the bladder using proliferative and quantitative markers: A multicentre study in 310 bladder tumors. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 530.e1-530.e8.	0.8	4
31	Long-term survival and complications following bladder-preserving brachytherapy in patients with cT1-T2 bladder cancer. Radiotherapy and Oncology, 2019, 141, 130-136.	0.3	11
32	Adding multiparametric MRI to the MSKCC and Partin nomograms for primary prostate cancer: Improving local tumor staging?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 181.e1-181.e6.	0.8	18
33	Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone. Journal of Nuclear Medicine, 2019, 60, 1111-1117.	2.8	23
34	Posterior, Anterior, and Periurethral Surgical Reconstruction of Urinary Continence Mechanisms in Robot-assisted Radical Prostatectomy: A Description and Video Compilation of Commonly Performed Surgical Techniques. European Urology, 2019, 76, 814-822.	0.9	41
35	Value of a Marker Lesion in Non-Muscle-Invasive Bladder Cancer Patients Treated with Interleukin-2 Instillations: A Randomized Controlled Multicentre Trial. Urologia Internationalis, 2019, 102, 69-76.	0.6	3
36	The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review. Epigenomics, 2018, 10, 673-687.	1.0	24

#	ARTICLE	IF	CITATIONS
37	The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with non-muscle-invasive bladder cancer. <i>BJU International</i> , 2018, 122, 571-575.	1.3	8
38	Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients. <i>European Urology</i> , 2018, 73, 226-232.	0.9	95
39	An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 400.e7-400.e14.	0.8	13
40	Reproducibility and Prognostic Performance of the 1973 and 2004 World Health Organization Classifications for Grade in Non-muscle-invasive Bladder Cancer: A Multicenter Study in 328 Bladder Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e985-e992.	0.9	19
41	Needle-based optical coherence tomography for the detection of prostate cancer: a visual and quantitative analysis in 20 patients. <i>Journal of Biomedical Optics</i> , 2018, 23, 1.	1.4	17
42	Primary Treatment for Prostate Cancer in an Elderly Man. <i>European Urology Focus</i> , 2017, 3, 325-326.	1.6	0
43	Effectiveness, cost-utility and implementation of a decision aid for patients with localised prostate cancer and their partners: study protocol of a stepped-wedge cluster randomised controlled trial. <i>BMJ Open</i> , 2017, 7, e015154.	0.8	6
44	Non-invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles. <i>Oncotarget</i> , 2016, 7, 22566-22578.	0.8	113
45	Development of a patient decision aid for the treatment of localised prostate cancer: a participatory design approach. <i>Journal of Clinical Nursing</i> , 2016, 25, 1131-1144.	1.4	21
46	Risk of disease flare with LHRH agonist therapy in men with prostate cancer: Myth or fact?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 7-15.	0.8	18